
Oscotec faces investor backlash over Genesco IPO as CEO warns of R&D shutdown
Oscotec’s plan to take its U.S.-based subsidiary Genosco public is under fire. Five months after filing for a Kosdaq listing, the biotech behind lazertinib—Korea’s first FDA-approved oncology drug—faces regulatory delays and growing investor backlash. Some …